Pfizer Raises 2026 Guidance: Eliquis and Cancer Drugs Exceed Expectations in Third Quarter

Pfizer's upward revision of its 2026 forecasts and better-than-expected results from Eliquis and its cancer drugs support the fundamental outlook. The price is trading at 30.78, above the SMA20 and SMA50, indicating a positive short-term trend. However, RSI14 stands at 65, and following a 4.75% rise over 24 hours, there is a short-term overbought risk. MACD is slightly above its signal line, with momentum weak but positive. I expect a moderate upward bias driven by the news, with a gradual climb rather than a sharp rally.

The given news headline pertains to Pfizer and has no direct connection to GOOGL's fundamental dynamics; therefore, no meaningful catalyst effect on the stock is expected. On the GOOGL side, a sharp 13.8% decline within 24 hours, the RSI approaching the oversold threshold at 30.7, and the price trading below both SMA20 and SMA50 indicate a weak short-term technical outlook. The MACD remaining below its signal line suggests that the downward momentum has not yet fully reversed. Due to oversold conditions, rebound buying may be seen within 1-3 days, but since the news impact is neutral, directional uncertainty persists. Therefore, I assess the short-term outlook as neutral.